Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Stopped early · Phase 2
Conditions studied: Head and Neck Cancer
In brief
Phase II trial to study the effectiveness of perifosine in treating patients who have recurrent or metastatic head and neck cancer. Drugs used in chemotherapy such as perifosine use different ways to stop tumor cells from dividing so they stop growing or die.
Key facts
- Study ID
- NCT00062387
- Run by
- National Cancer Institute (NCI)
- People needed
- 46
- Starts
- 2003-05-01
- Expected to finish
- 2007-01-01
- Last updated by the study team
- 2013-06-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Chicago Cancer Research Center — Chicago, Illinois, United States
- Decatur Memorial Hospital Cancer Care Institute — Decatur, Illinois, United States
- Evanston Northwestern Health Care - Evanston Hospital — Evanston, Illinois, United States
- Ingalls Memorial Hospital — Harvey, Illinois, United States
- LaGrange Memorial Hospital — LaGrange, Illinois, United States
- Cardinal Bernardin Cancer Center at Loyola University Medical Center — Maywood, Illinois, United States
- Oncology/Hematology Associates of Central Illinois, P.C. — Peoria, Illinois, United States
- Central Illinois Hematology Oncology Center — Springfield, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Incorporated — Fort Wayne, Indiana, United States
- CCOP - Northern Indiana CR Consortium — South Bend, Indiana, United States
- Oncology Care Associates, P.L.L.C. — Saint Joseph, Michigan, United States
- Medical College of Wisconsin Cancer Center — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.